An FDA panel endorsed the approval of Janssen R&D Ireland and Medivir's simeprevir, in combination with peginterferon alfa and ribavirin, as a treatment for chronic hepatitis C in patients with compensated liver disease. The drug was particularly recommended for previously untreated patients or those who were unresponsive to previous interferon treatment with or without ribavirin. If approved, the drug would be the third HCV protease inhibitor available in the U.S.
Janssen's hepatitis C drug simeprevir wins support of FDA panel
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||